Company Summary
Search
Home Page
 
*Thallion Pharmaceuticals Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
October 31DelistN
Board of Directors
NamePosition
(not available)
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
22/Jul/2009 20/Aug/2013 Canada Quebec  
Exchange Filing Office
Location
(not available)
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  *Research and Development in the Physical, Engineering and Life Sciences  From News Release April 24, 2013 - Thallion Pharmaceuticals Inc. (TSX-V: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's lead clinical program Shigamabs? is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has recently completed a Ph II clinical trial. Additional information about Thallion can be obtained at www.thallion.com. 
Securities
SymbolSecurity NameMarketStatus
*TLN*Thallion Pharmaceuticals Inc.TSX VentureDELIST
Name HistoryFromTo
*Thallion Pharmaceuticals Inc.4/Oct/201220/Aug/2013
Company Facts Reconciliation
SubjectDate Returned
Summer 2013 CFRNot Received
Associations
Auditing Firm:  *KPMG (Montreal)
Transfer Agent:  *Computershare Trust Company of Canada (Montreal)
Latest Information
TypeDateTitle
News Releases  15/Aug/2013  NEWS RELEASE - BELLUS ANNOUNCES CLOSING OF THE ACQUISITION OF T[MARKET NEWS]
    NEWS RELEASE - THALLION PHARMACEUTIQUES ANNONCE UNE COMPOSANTE AU COMPTANT DE 0 1889 $ PAR ACTION[MARKETWIRE]
    NEWS RELEASE - THALLION PHARMACEUTICALS ANNOUNCES CASH COMPONENT OF $0.1889 PER SHARE[MARKETWIRE]
Bulletins  20/Aug/2013  Delist
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data